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MOLECULAR SCREENING OF MYOCILIN GENE IN PATIENTS 
WITH POSITIVE FAMILY HISTORY OF GLAUCOMA 
ABSTRACT: 
AIM: To screen myocilin gene for known/unknown variations in patients with 
positive family history of glaucoma. 
METHODOLOGY: All patients underwent a thorough ophthalmological 
examination after obtaining a detailed family history with custom designed 
questionnaire. On securing informed consent, the blood samples were collected 
from probands and their available family members and subjected to DNA 
analysis. DNA was isolated using Phenol-Chloroform-iso amyl alcohol method 
and amplified using polymerase chain reaction. Purified PCR product was then 
directly sequenced using forward primer. The sequences were aligned for 
homology with their respective reference sequences using NCBI BLASTN and 
analysed for probable sequence variations. 
RESULTS: A total  of  35 subjects  were included in this  study.  Majority of  the 
probands were females in the age group of 50-70 years. DNA analysis was done 
which showed exonic variations in six of the probands of which three had 
variations in exon 1, two in exon 3 and one had in both exon 1 and exon 3. All 
these exonic variations were found to be heterozygous except two that were 
homozygous. The proband DKEG12A had four exonic variations one in exon 1 
viz., R76K which was homozygous and other three were in exon 3 as T325M , 
L349L, R470R  all were heterozygous. The change T325M is a novel variation. 
The proband DKEG11A had Q368X in heterozygous state which is a truncated 
mutation. Intronic variations were noted in proband DKEG3A, DKEG4A, 
DKEG5A, DKEG7A, DKEG9A, DKEG10A, and DKEG12A of which some of 
them were homozygous and some were of heterozygous.  
CONCLUSION: The truncated mutation Q368X has been found for the first 
time in south Indian population, though previous studies have documented this 
mutation in western as well as in north Indian population. Two novel 
synonymous variations L349L, R470R are being documented for the first time 
to be in association with glaucoma. The novel variation T325M has to be 
functionally characterised. Thus molecular screening may open an exciting 
frontier in the future to aid in early diagnosis and treatment of glaucoma.  
KEYWORDS: Hereditary,POAG,Myocilin,Genetic testing  
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INTRODUCTION 
Glaucoma is defined as chronic progressive optic neuropathy 
characterized by structural changes in the optic nerve head with 
corresponding visual field defects for which increased intraocular 
pressure, the only modifiable parameter, is the most important risk factor. 
Detection of glaucoma at its earlier stage and monitoring its 
progression is critically important for successful management of 
glaucoma patients. Often there occurs visual loss which goes unnoticed 
and patients may present only in the late stages when significant damage 
has already occurred. As the damage occurred is not reversible with 
medications or any other mode of treatment, identification in the early 
stages and appropriate treatment may prevent further progression of the 
disease and helps in retaining useful vision for the patient. 
Several gene mutations have been known to be associated with 
glaucoma. To date there have been over 20 genetic loci and 3 genes 
MYOC (Myocilin), OPTN (Optineurin) and WDR36 that have been 
linked to POAG. A positive family history was found as an important risk 
factor for primary open angle glaucoma (POAG) in population based 
studies1. So identification of gene mutations among siblings and parents 
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of those with positive family history will help in early detection and thus 
appropriate management can be done before significant visual loss occurs 
and also broaden our understanding in the field of molecular genetics in 
relation to glaucoma helping us to diagnose this dreadful disease even 
before it sets in to manifest clinically. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF 
LITERATURE 
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Glaucoma, the second leading cause of blindness, is characterized 
by changes in the optic nerve head with corresponding visual field 
defects. It is characterized by loss of retinal ganglion cells (RGC) and 
their axons.  The intraocular pressure (IOP) was considered to be the 
prime risk factor responsible for the glaucomatous optic neuropathy and it 
is the only modifiable parameter towards which all treatment protocols 
are addressed to.  
ANATOMICAL STRUCTURES RELATED TO GLAUCOMA: 
CILIARY BODY:   
It is the portion of the uveal tract that lies between the iris and the 
choroid. It attaches to the scleral spur and creates a potential space, the 
supraciliary space, between itself and the sclera.  
Ciliary body is composed of two parts – the innermost and anterior 
most regions is called the pars plicata comprising the ciliary processes 
which is the actual site of aqueous humor production and a posterior 
portion called the pars plana.    
 
ANATOMY OF ANGLE OF ANTERIOR CHAMBER 
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The pars plicata region is composed of smooth muscle, which 
serves the important functions of accommodation and uveoscleral 
outflow. The pars plana, has a flatter inner surface and joins the choroid 
at the ora serrata. The lens is suspended from the ciliary body by zonules. 
TRABECULAR MESHWORK: 
Trabecular meshwork is a sponge like connective tissue which lies 
in  the  angle  of  the  anterior  chamber  with  the  canal  of  schlemm’s  on  its  
outer aspect. It is responsible for draining the aqueous humour from the 
eye through the anterior chamber. The trabecular meshwork is 
anatomically divided into 3 parts , each part having a different 
ultrastructure.  
• Inner uveoscleral meshwork  
• The corneoscleral meshwork  
• The outermost juxtacanalicular portion that lies beneath the inner wall 
of Schlemm’s canal and this layer is considered to be the main site of 
resistance to aqueous humor outflow.  
Aqueous humour passes from anterior chamber through inter and 
intra trabecular spaces. These spaces are lined by trabeculocytes which 
maintain the state of hydration of the connective tissue core and also has 
LAYERS OF THE TRABECULAR MESHWORK 
 
 
 
 
 
 
 
 
 
 
INNER WALL OF SCHLEMM’S CANAL AND  JUXTACANALICULAR MESHWORK 
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a  phagocytic action that  helps in trapping and removing debris from the 
aqueous humour as it percolates through these spaces which narrows 
down as the Schlemm’s canal is approached.  
SCHLEMM'S CANALǣ
It is an endothelial lined oval channel present circumferentially in 
the scleral sulcus. The endothelial cells lining the inner wall are irregular; 
spindle shaped and contains giant vacuoles while those lining the outer 
wall are smooth and flat. The outer wall has numerous openings of 
collector channels which ultimately drain into the episcleral veins via 
direct and indirect system. 
POSTERIOR CHAMBER  
It is a triangular space bounded anteriorly by posterior surface of 
the iris and part of ciliary body and posteriorly by the lens and its zonules 
and contains around 0.06ml of aqueous humor.  
ANTERIOR CHAMBER  
It is bounded anteriorly by the back of the cornea and posteriorly 
by the anterior surface of iris and part of ciliary body. It is about 2.5mm 
deep and contains about 0.25ml of the aqueous humor. Its peripheral 
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recess is called the angle of the anterior chamber which is mainly formed 
by the trabecular meshwork. 
ANGLE OF THE ANTERIOR CHAMBER  
From posterior to anterior the angle recess is formed by the 
following structures:- 
x Ciliary body band : 
It is the posterior most landmark in the angle recess formed by the 
anterior most part of the ciliary body between its attachment to the scleral 
spur and insertion of the iris. It appears as a grey or dark brown band in 
gonioscopy. 
x Scleral spur : 
It is the posterior portion of the scleral sulcus which usually 
appears as a prominent white line on gonioscopy. 
x Trabecular meshwork  
It is seen as a band just anterior to scleral spur . It has no pigment 
at birth and develops pigment with increasing age. 
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x Schwalbe’s line : 
It marks the anterior limit of the structures forming the angle of the 
anterior chamber formed by the termination of the descemet’s membrane 
of the cornea seen as a glistening white line. 
AQUEOUS HUMOUR:  
Aqueous humour is transparent, clear, slightly alkaline fluid which 
occupies the anterior and posterior chambers of the eye. It resembles 
blood plasma in composition but composed of less protein and glucose 
and more lactic acid and ascorbic acid. It has multiple physiologic 
functions throughout the various ocular structures. It provides nutrients 
and oxygen to ocular tissues that lack a direct blood supply such as the 
lens and cornea and also removes their metabolic waste products. 
Additionally, it is also responsible for maintaining the intraocular 
pressure (IOP) which is needed to maintain the integrity of the eyeball. 
AQUEOUS HUMOUR DYNAMICS 
There exists a dynamic balance between aqueous humor production 
and its outflow which helps to maintain the normal intraocular pressure. 
The two main structures related to aqueous humor dynamics are the 
 AQUEOUS HUMOR DYNAMICS       
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ciliary body, the site of aqueous humor production and the trabecular 
meshwork the principal site of aqueous humor outflow. 
SECRETION OF AQUEOUS HUMOUR:  
Aqueous humour is derived from blood plasma within the capillary 
network of the ciliary processes by three mechanisms:  
• Diffusion: It is the process wherein there is a passive movement of ions 
across a membrane related to charge and concentration. 
 • Ultra filtration: Water and water-soluble substances, limited by size 
and charge, are transported across the cell membrane pores in response to 
an osmotic gradient or hydrostatic pressure which in turn is influenced by 
IOP, blood pressure in the ciliary capillaries, and plasma oncotic 
pressure.  
 Diffusion and ultrafiltration are both passive mechanisms, with 
lipid and water soluble substances from the capillary core traversing the 
stroma and passing through pigmented epithelial cells and limited by the 
tight junctions of the non-pigmented epithelial cells. 
 • Active transport (secretion): Water-soluble substances of larger size 
or greater charge are actively transported across the cell membrane .This 
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process requires the expenditure of energy which is derived from the Na-
K ATPase pump and glycolytic enzymes present in nonpigmented 
epithelial cells. Active transport accounts for the majority of aqueous 
production.  
AQUEOUS OUTFLOW PATHWAYS:  
There are two main pathways of aqueous humor outflow which is 
involved in control of IOP. 70-90% of aqueous humor leaves the anterior 
chamber through the conventional outflow pathway (trabecular 
meshwork and Schlemm’s canal) and enters the episcleral veins. A 
proportion of aqueous humour (10-30%)  drains via the non conventional 
outflow path way (intercellular spaces between ciliary muscle fibers and 
the loose connective tissue of the suprachoroidal space). 
PATHOPHYSIOLOGY OF GLAUCOMA  
Glaucoma is a chronic progressive disease characterized by slow 
and progressive degeneration of retinal ganglion cells (RGC’s).This 
results in decrease in the neuroretinal rim width with concomitant 
enlargement of the cup.  
The pathophysiological mechanisms underlying the glaucomas are 
not fully understood. 
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There are two main mechanisms proposed for glaucomatous damage of 
retinal ganglion cells.2 
1. Mechanical theory – Raised IOP causing mechanical compression of 
the retinal ganglion cell  axons thereby interrupting the axonal flow and 
causing cell death 
2. Ischemic theory – Development of intraneuronal ischemia due to 
decreased ocular perfusion and thereby causing death of the ganglion cell 
axons. 
Several other possible mechanisms have been proposed which are 
unrelated to IOP. These include excessive retinal glutamate, deprivation 
of neuronal growth factors, free nitrate radicals, immune mediated nerve 
damage and oxidative stress which may also contribute to the initiation 
and progression of glaucoma.2Nevertheless, the molecular mechanisms 
responsible for impaired aqueous outflow in glaucoma are still not clear.3 
CLASSIFICATION OF GLAUCOMA  
There are several ways in which glaucoma can be classified such as 
based on anatomic, gonioscopic, biochemical and molecular and genetic 
features.4 
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However traditionally they are classified into either open angle or 
closed angle and whether primary or secondary. Glaucomas are classified 
as primary when they occur with no known etiology or as secondary 
when  they  are  associated  with  other  ocular  and  systemic  disorders.  In  
general, glaucomas may be categorized into three major types:  
 • Primary open-angle glaucoma (POAG)  
 • Primary congenital glaucoma (PCG)  
 • Primary angle closure glaucoma (PACG)  
EPIDEMIOLOGY OF GLAUCOMA 
Among 285 million people who are visually impaired worldwide, 
39 million are blind and 246 million have low vision. Glaucoma is 
recognized to be the second most common cause for bilateral blindness 
and constitutes about 8% of the causes for global blindness.5 
According to the World Health Organization statistics which was 
published in 2010, glaucoma accounts for blindness in 4.5 million 
persons behind only cataracts at 18 million person6. In India glaucoma 
accounts for blindness in about 1.5 million people .7The number of 
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people affected with glaucoma is supposed to increase to almost 80 
million by 2020.6 
PRIMARY OPEN ANGLE GLAUCOMA  
Primary open angle glaucoma (POAG) is the most common type of 
glaucoma. Its incidence increases with increasing age affecting 1-2% of 
all  individuals  over  the  age  of  40  years  which  increases  to  8-10% in  65  
years and above age group. POAG is found to be more prevalent in 
Africans than in Caucasian and Asians. Several population-based studies 
done in southern India have reported various prevalence rates of primary 
open-angle glaucoma. The prevalence of POAG in the Chennai 
Glaucoma study was 1.62%.8 
Primary open-angle glaucoma (POAG) is defined as chronic, 
progressive, anterior optic neuropathy which is accompanied by 
characteristic optic disc changes, visual field loss, and open angles, 
having no obvious causative ocular or systemic conditions9. The most 
important risk factor, though not the only cause of all damage, being 
elevated intraocular pressure (IOP) probably reflecting a reduced aqueous 
humor outflow facility. There are several other risk factors other than 
elevated IOP such as age, race, gender, heredity, socioeconomic status, 
PRIMARY OPEN ANGLE GLAUCOMA 
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myopia, diabetes etc... Of all this heredity i.e. family history has been 
found to be significantly associated with POAG.9, 10 
Around  5–50%  of  cases  of  POAG  are  hereditary,  the  risk  of  
developing POAG in first degree relatives being 4–16%9. The likelihood 
of relatives of patients with POAG developing glaucoma was 10 times 
more than relatives of those without glaucoma. Furthermore, siblings 
of those individuals with glaucoma have been found to have a higher IOP 
and a larger cup-to-disc ratio than siblings of those without glaucoma. 
The  onset  of  this  disease  is  usually  insidious  and  has  a  slowly  
progressive course which may present as either progressive loss of vision 
or may remain completely asymptomatic being detected incidentally on 
routine clinical examination. Intraocular pressure is elevated in most of 
the patients and is found mostly to be in the range of 22-40mmhg. 
Gonioscopy shows open angles. Fundus examination shows characteristic 
optic disc cupping with nasalization, bayoneting, neuroretinal rim 
thinning etc. along with corresponding visual field defects.  
The main goal of treatment is to improve the patient’s life by 
improving or preserving visual function without causing undue problems 
occurring due to therapy. Treatment has to be individualized depending 
on the degree of the glaucomatous damage, rate of change of patient’s 
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clinical condition and the presence of associated risk factors. The target 
pressure should be estimated for each patient in order to prevent further 
damage. Main modality of treatment is lowering the IOP with topical 
antiglaucoma medications although argon laser trabeculoplasty is also an 
appropriate initial treatment. Filtration surgery is usually preferred if 
patient is not responding to medical/laser treatment  or is intolerant to 
topical medications . 
PRIMARY ANGLE CLOSURE GLAUCOMA  
Primary angle closure glaucoma is due to appositional or synechial 
closure of the angle of the anterior chamber angle caused by pupillary 
block in the absence of other causes of angle closure.  
Classification of angle closure glaucoma 
x Primary angle closure suspect:  Greater than 270 degree of irido-
trabecular contact plus absence of peripheral anterior synechiae plus 
normal IOP, disc, and visual field. The angle is at risk. 
x Primary angle closure: Greater than 270 degree of irido-trabecular 
contact  with  elevated  IOP  and/  or  peripheral  anterior  synechiae  plus  
normal disc and visual field examinations. The angle is abnormal in 
structure or function. 
15 
 
x Primary angle closure glaucoma: Greater than 270 degree of irido-
trabecular contact plus elevated IOP plus optic nerve and visual field 
damage. The angle is abnormal in structure and function with optic 
neuropathy. 
Commonly presents in sixth and seventh decades of life being 
more common in women compared to men. Most of the cases are 
sporadic in nature though few studies have shown autosomal dominant 
and recessive mode of inheritance. Prevalence is more in hyperopic eyes. 
Several ocular risk factors have been proposed which include  
x Shallow anterior chamber 
x Decreased anterior chamber volume  
x Short axial length  
x Small corneal diameter  
x Increased posterior corneal curvature 
x Decreased corneal height  
x Increased thickness and anterior curvature of the lens  
x More anterior insertion of iris into the ciliary body  
The underlying pathophysiology is the development of relative 
pupillary block in patients with above risk factors leading to impairment 
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of aqueous outflow and thereby a raise in intraocular pressure. Several 
factors can trigger a relative pupillary block resulting in an acute attack in 
patients with predisposing risk factors which include dim illumination, 
emotional stress, topical or systemic use of cycloplegic or mydriatic, 
etc… 
Symptoms include sudden development of redness, pain, haloes 
and diminished vision. On examination, IOP is elevated associated with 
corneal edema, mid-dilated pupil with poor reaction and a shallow 
anterior chamber. Gonioscopy done once corneal edema clears shows 
presence of closed angles. Optic disc is edematous and hyperemic in case 
of acute attack. But patients who have had recurrent attacks and have 
chronic angle closure usually show characteristic cupping and vessel 
changes. Examination of the fellow eye shows shallow anterior chamber 
with occludable angles. Treatment includes laser peripheral iridotomy in 
patients with occludable angles especially those not expected to turn up 
for regular follow ups. Acute elevations of IOP can be controlled by 
topical and systemic antiglaucoma medications. Definitive treatment is 
filtering surgery. 
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PRIMARY CONGENITAL GLAUCOMA 
This  is  a  rare  condition  which  is  the  most  common  form  of  
glaucoma in infants and more than 80% of cases manifest within the first 
year  of  life.  The  exact  cause  is  unknown.  It  is  possibly  due  to  
maldevelopment of angle structures during development. The clinical 
findings typically consist of epiphora, photophobia, corneal edema and 
buphthalmos. Goniotomy or trabeculotomy is the first line treatment, 
second choice is guarded filtering procedure and third choice is tube 
shunt surgery. Management of corneal haziness, refractive changes and 
efforts to prevent amblyopia is essential. 
DIAGNOSIS OF GLAUCOMA  
Single test is not sufficient to diagnose glaucoma. Currently 
diagnosis is based on correlating several factors mainly IOP, optic disc 
damage with corresponding visual field defects. Close attention is given 
to elevated IOP and a positive family history of the disease. Diagnosis of 
glaucoma especially POAG requires comprehensive history taking and  
examination including  visual acuity, slit lamp biomicroscopy, CCT 
corrected Goldmann applanation tonometry, gonioscopy, optic nerve 
head assessment, retinal nerve fiber layer assessment and visual field 
testing .  
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TONOMETRY 
Tonometry is defined as the measurement of intraocular pressure. 
A tonometer is an instrument used for measuring tension or pressure. 
Classification of Tonometers 
All clinical tonometers measure the IOP by relating a deformation 
of the globe to the force responsible for the deformation. 
The two basic types of tonometers differ according to the shape of 
the deformation: indentation and applanation (flattening). 
Indentation Tonometers 
In indentation tonometry, a known weight is placed on the cornea, 
and the IOP is estimated by measuring the deformation or indentation of 
the globe. The Schiotz tonometer is the prototype for this class of 
instruments. 
Applanation tonometers 
The applanation  tonometers are further differentiated on the basis 
of the variable that is measured. 
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Variable Force 
This type of tonometer measures the force that is required to 
applanate (flatten) a standard area of the corneal surface. The prototype is 
the Goldmann applanation tonometer, which was introduced in 1954. 
Variable Area 
This type of tonometer measures the area of the cornea that is 
flattened by a known force (weight). The prototype in this group is the 
Maklakoff tonometer, which was introduced in 1885. 
Goldmann type tonometers have relatively minimal displacement, 
whereas that with Maklakoff-type tonometers is sufficiently large to 
require the use of conversion tables. 
Goldmann tonometry is considered to be the gold standard in 
tonometry. It is based on the principle of the Imbert-Fick law. This law 
states that an external force (W) against a sphere equals the pressure in 
the sphere (Pt) multiplied by the area flattened (applanated) by the 
external force (A): 
 W=Pt X A 
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The procedure consists of adjusting the force applied by a 
tonometer tip on the central cornea to anesthetized eye until the observer 
is satisfied with the pattern produced by the visible fluorescence of the 
precorneal tear film. The force (in grams) is multiplied by ten and is 
assumed to be IOP expressed as mmHg. Perkins tonometry is used for 
examination of infants under anesthesia. Perkins tonometer is a special 
type of portable applanation tonometer, which allows measurement of 
IOP in children, patients unable to cooperate for slit lamp examination, 
and in anaesthetised patients who may be in a supine position.  
Noncontact Tonometer 
A third  type  of  tonometer  uses  a  puff  of  air  to  deform the  cornea  
and measures the time or force of the air puff that is required to create a 
standard amount of corneal deformation.  
GONIOSCOPY: 
Gonioscopy is the method of visualizing the anterior chamber 
angle to know whether it is open or closed. It is essential in diagnosing 
the type and etiology of glaucoma and also is helpful prognostically and 
therapeutically in glaucoma. 
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There are 2 types of gonioscopy – Direct and Indirect  
Direct gonioscopy: 
Uses Koeppe lens to visualize the angles. The surface of this lens is 
quite large and needs the use of saline or similar fluid as a coupling agent, 
and this necessitates that the patient should lie supine. However has the 
advantage of giving a panoramic view of the angle structures. The 
curvature of this lens adds 1.53 to the magnification of the angle image. 
Lighting is usually obtained by a Barkan hand held illuminator or fiber 
optic light source, and magnification is obtained by a supported, 
counterbalanced microscope having 1.63 objective lenses. 
Indirect gonioscopy:  
Two types of gonioscopic contact lenses are available: (1) those 
whose surface is slightly larger than the cornea and that require a 
gonioscopic coupling gel (e.g., Goldmann lens)  (2) those whose surface 
is smaller than the cornea and that use the patient’s tear film as a coupling 
agent (e.g., Zeiss or Sussman four-mirror lens) 
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Goldmann and Zeiss lenses: 
These types of lenses are termed indirect gonioscopic lenses 
because they have mirrors by which the angle is examined with reflected 
light 
VISUAL FIELDS 
Evaluation of visual fields plays an important role in the diagnosis 
of glaucoma. Visual fields can be evaluated using two types of techniques  
1. Kinetic perimetry 
2. Static perimetry 
Kinetic perimetry: 
In  this  case  the  stimulus  is  of  the  same  intensity  and  only  the  
location of the stimulus is changed. 
Static perimetry: 
Here the stimulus is stationary or static whereas the size and 
intensity of the stimulus can be varied  
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The static automated perimetry is available in  
1. Octopus perimeter 
2. Humphrey field analyzer 
ASSESSMENT OF FIELDS BY AUTOMATED PERIMETRY 
Automated perimetry is the standard method of measuring the 
visual field. The standard protocol of static white on white stimuli is 
called standard automated perimetry. A major limitation of tangent screen 
and arc perimeters was a lack of standardization of test objects and the 
background as well as the patient’s fixation. 
Since automated perimetry is a computerized method of evaluating 
the visual fields it has provided the following advantages over manual 
perimetry 
1. Random presentation of targets to avoid patient anticipation of the 
next presentation sites 
2. Estimation of patient’s reliability 
3. Reduced variability  
4. Ability to determine the extent of decrease in the retinal sensitivity at 
each point 
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TESTING PATTERNS 
The central 24-30 degrees field with 6 degree separation between 
test locations is commonly used test pattern. In case of tubular fields as 
occurs in advanced glaucoma the central 10 degree of field is tested to 
know how much of central field is preserved and this also helps in 
deciding whether the patient can be taken up for ant glaucoma surgery in 
order to prevent the snuff out phenomenon post operatively. 
TESTING STRATEGIES: 
Several strategies are available namely full threshold, Tendency 
oriented perimetry (TOP), FASTPAC, Swedish interactive threshold 
algorithm (SITA). 
Full threshold strategy tests more points and takes a longer time to 
assess the visual fields. This may cause fatigability of the patients thereby 
making the field analysis unreliable. To overcome this problem and to 
make the test simpler and more reliable as well as comfortable for the 
patients, faster strategies were introduced. These include TOP, 
FASTPAC  and  SITA  strategies  of  which  the  former  one  belongs  to  
Octopus and latter two strategies were incorporated in Humphrey. TOP 
uses a computational approach to estimate threshold values by 
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extrapolating information from the surrounding test points. FASTPAC 
reduces the testing time by using a single threshold crossing in 3 db 
increments instead of standard double threshold crossing to estimate the 
visual field defects. 
INTERPRETATION OF RESULTS 
Reliability of the test is assessed by determining the number of 
false positives and false negatives as well as the frequency of fixation loss 
and number of stimuli required to complete the test.  
Octopus provides printout with probability, corrected probability 
and comparison, corrected comparison. 
Global indices are mathematically analyzed data allowing detection 
of more subtle visual field abnormalities. It comprises of mean sensitivity 
which is the average of the patient’s responses for all the points tested. 
Mean defect/deviation refers to the measurement of how the mean of the 
patient’s responses varies from the mean of the responses of a series of 
normal patients of similar age under similar testing conditions. These 
indices primarily reflect diffuse changes. The way to detect localized 
defect is to calculate the number of threshold values that deviate 
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significantly from the age corrected normal which is called loss variance. 
Corrected loss variance takes into account the short term fluctuation. 
Field defects commonly seen in glaucoma are: 
1) Para central Scotoma / Bjerrum Scotoma 
2) Seidel scotoma  
3) Arcuate Scotoma 
4) Isolated Arcuate scotoma 
5) Ronne’s Nasal Step 
6) Peripheral temporal breakthrough 
7) Central or temporal island 
OPTICAL COHERENCE TOMOGRAPHY 
Optical coherence tomography (OCT) is an imaging modality that 
employs near-infrared light to create cross sectional images of the retina 
and optic nerve, thereby allowing analysis of the optic nerve head, 
macula, and retinal nerve fiber layer (RNFL).It is based on the principle 
of Michelson’s laser interferometry and  is a non-invasive and rapidly 
obtained imaging test that provides detailed information about the 
posterior segment.  It shows cross sectional living histology of retina with 
high resolution and reproducibility.  
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OCT has been shown to have good reproducibility of RNFL 
thickness measures, suggesting it may be a useful clinical tool to monitor 
glaucomatous disease progression.OCT also helps in early detection of 
glaucoma even before visual field defects become apparent and hence is 
an important tool in the diagnosis of pre perimetric stage of glaucoma  
GENETICS IN GLAUCOMA 
The molecular etiology of glaucoma is largely unknown, but there 
are numerous studies establishing a genetic etiology for this disorder. 
Understanding the molecular basis of glaucoma is important to several 
aspects of glaucoma diagnosis and management. Genetic testing could be 
used to identify individuals who are at high risk for the development or 
progression of glaucoma. Identifying novel pathways could be used to 
design more specific and effective therapies.  
BASIC GENETICS 
Every individual has about 23 pairs of chromosomes which 
comprises  of  22  autosomal  pairs  and  one  sex  pair  which  contain  either  
two X chromosomes  (female)  or  one  X and  one  Y chromosome (male).  
Each human chromosome is  made up of thousands of genes which in 
turn are arrayed along one molecule of DNA. Each chromosome pair 
 STRUCTURE OF NORMAL DNA 
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consists of one DNA molecule from each parent. The DNA is made up of 
nucleotides. Each nucleotide is formed by varying sequences of four 
nucleic acid bases. The nucleic acid bases are divided into two groups 
purines (adenine and guanine) and pyrimidines (thymidine and 
cytosil/uracil). 
A codon refers to series of three nucleic acid base pairs. It is the 
sequence of the base pairs and codons that determine the nature of the 
amino acid and protein synthesis directed by the DNA nucleotide, and it 
is the protein which determines the phenotypic trait of an individual. 
DNA is the template from which RNA is made by a process known as 
transcription and RNA governs protein synthesis inside the cell. Groups 
of DNA bases that are transcribed into messenger RNA which results in 
protein synthesis are called exons and the DNA strands that form inactive 
mRNA in between the exons are called introns. 
GENETIC NOMENCLATURE 
The human genome organization (HUGO) designates the locus of 
the gene. The first three letters usually indicate the broad category of the 
disease state. For example, GLC indicates it is a primary glaucoma rather 
than a secondary glaucoma. The numbers 1, 2, 3, etc., following the first 
three letters indicates the type of glaucoma. 1 denotes open angle, 2 
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denotes closed angle and 3 denotes congenital glaucoma. Depending on 
the chronological order of identification, each newly mapped gene is 
given a sequential letter such as ‘a’ is for the first, ‘b’ for the second gene 
identified, and so on 
GENES AND LOCI ASSOCIATED WITH GLAUCOMA9  
Locus 
Location 
or 
reference 
Gene 
orproteinname 
 
Phenotype Age of onset Inheritance 
Per cent of 
phenotype 
withgene 
GLC1A 1q23-q25  TIGR/myocilin JOAG/POAG Juvenile/adult Dominant 3 
GLC1B 2cen-q13         -     POAG  Adult Dominant Very low 
GLC1C 3q21-24      POAG Adult Dominant Very low 
GLC1D 8q23      POAG Adult Dominant Very low 
GLC1E 10p15-14 Optineurin POAG/NTG Adult Dominant 5 
GLC1F 7q35     POAG Adult Dominant Very low 
OPA1 3q28 OPA1     NTD Adult         ?   ~30% 
GLC3A 2p21 CYP1B1 Congenital Infant Recessive  Majority 
GLC3B 1p36  Congenital Infant Recessive  
NNOS 11  
Angle closure/ 
Nanopthalmos 
Young–older adult Dominant Majority 
RIEG1 4q25 PITX2 Rieger syndrome Infant–childhood 
Dominant 
 
 
RIEG2 13q14 FOXC1 Rieger syndrome Infant–childhood 
Dominant 
 
 
IRID1 
6p25 
7q35 
FKHL7 
    - 
Iridogoniodysgenesis 
Pigment dispersion 
Infant–child 
Young adult 
Dominant 
 
 
NPS 9q34 LMX1B Nail-patella syndrome Young adult 
Dominant 
 
 
PAX6   Aniridia Congenital   
LOXL1 
 
15q21 Lysyl oxidase 
Exfoliation 
syndrome 
and glaucoma 
Late adult       ? 
5–10% 
 
JOAG, juvenile-onset open-angle glaucoma; NTD, neural tube defect; POAG, primary open-angle glaucoma. 
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To date there have been over 20 genetic loci and 3 genes MYOC 
(myocilin) , OPTN (optineurin) and WDR36 that have been linked to 
POAG.11      
MYOC   
This was the first gene to be associated with the development of 
POAG.It was previously known as TM inducible glucocorticoid response 
protein or TIGR which was initially localized to GLC1A locus. It was 
then subsequently linked to the MYOC gene. Over 70 different point 
mutations have been identified in MYOC gene in multiple ethnic groups 
worldwide11. Most of them were located in the coding regions of the gene 
and  are  associated  with  3-5%  of  POAG  cases  throughout  the  world.  In  
India MYOC gene mutations has been identified in only 2% of the 
population with POAG.12 
It is expressed in multiple ocular and non ocular tissues. Its exact 
function is not yet known. It consists of 3 exons and contains 504 amino 
acids and has a predicted molecular weight of approximately 57kDa.Has 
2 major domains with an N-terminal myosin-like domain and C-terminal 
olfactomedin –like domain. The N-terminal is encoded by exon 1 and C-
terminal by exon 3.The myosin-like domain seems to be more variable 
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between species except for a highly conserved leucine-zipper element and 
the olfactomedin domain is also well preserved across the species. 
Myocilin is found in many tissues and organs of the body and 
throughout most ocular structures, the highest being in iris, sclera and 
trabecular meshwork. 
Most common mutations include Glu229Lys, Arg368His, 
Gln368Stop, etc. The common mutation Gln368Stop found in the western 
population was not observed in the POAG cases screened in Indian 
population. Mutation frequency of the MYOC gene is only 2% in the 
Indian population12. But another study states Gln48His is the prevalent 
myocilin mutation in POAG and primary congenital glaucoma 
phenotypes in India.13 
OPTINEURIN  
This gene has been localised to the GLC1E locus on chromosome 
10p14 in the year 1998. It was then subsequently linked to OPTN gene in 
2002. It was previously known as FIP-2. Its expression has been localised 
to several non ocular and ocular tissues. Because optineurin in expressed 
in the retina and because it is associated with cellular apoptosis, it was 
thought that mutations in this gene could possibly explain why the optic 
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nerves of the patients with normal pressure glaucoma are more 
susceptible to optic nerve deterioration. It consists of 16 exons and its 
exact function and how its mutations lead on to glaucoma is unknown. 
Overall it accounts for <1% of open angle glaucoma. Studies done using 
this as a candidate gene does not suggest a significant involvement of 
OPTN in   POAG patients of Indian origin14. Further studies are required 
to determine the exact function of OPTN and to find out the exact 
mechanism through which mutations in OPTN lead to development of 
glaucoma  
WDR36 
This gene was initially localised to GLC1G locus at chromosome 
5q22.1 and then subsequently linked to WDR36 in 2006. It is a 23 exon 
gene. It is found in several intraocular structures and several organs 
including the heart, liver and kidneys. Initial studies showed an 
association of this gene in 5% of POAG cases. But subsequent studies 
have shown low and no associations of WDR36 and open angle 
glaucoma. The exact role of this gene in pathogenesis of POAG needs 
further investigations.  
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GENE ASSOCIATED WITH PRIMARY CONGENITAL 
GLAUCOMA (PCG) 
Inheritance of PCG is usually sporadic in most of the cases but 
sometimes can present with autosomal recessive mode of inheritance. It is 
more common in the Middle East and in Gypsies probably because of the 
higher prevalence of consanguinity in these cultures9. There are 3 
different genetic loci which have been linked to date in PCG. The first 
two loci identified (GLC3A and GLC3B) were mapped to chromosome 2 
(2p21) and chromosome 1 (1p36.2-p36.1) respectively. The third locus 
GLC3C was mapped to chromosome locus 14q24.3.Only GLC3A locus 
has been linked to a specific gene. This gene is called CYP1B1, the 
largest  known enzyme of  the  human cytochrome –p  450  pathways.  It  is  
the first gene in this well known family to result in primary 
developmental defect.  
Several mutations have been identified in CYP1B1 which 
primarily consists of insertions or deletions of the gene. Studies have 
identified CYP1B1 as a causative gene in primary congenital glaucoma 
and as a modifier gene in POAG. Rarely may it act as a causative factor 
for several anterior segment dysgenesis disorders.  
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GENES ASSOCIATED WITH PRIMARY ANGLE CLOSURE 
GLAUCOMA (PACG) 
Most of the cases of PACG are sporadic in nature and don’t have a 
positive family history. There are no specific genes which have been 
linked to the development of PACG, though several pedigrees are 
reported to have a high prevalence of PACG. 
Some pedigrees showed autosomal dominant and some showed 
autosomal recessive pattern of inheritance. The shallower the anterior 
chamber more is the risk for primary angle-closure glaucoma. Certain 
other factors like increasing thickness of lens with age also leads to 
shallowing of the anterior chamber further increasing the risk of angle 
closure glaucoma. However recent studies have reported a single 
nucleotide pleomorphism in MMP-9 gene to be associated with angle 
closure glaucoma.10 
Having gone through various studies , it is very interesting to know 
that molecular screening of genes may  open an exciting frontier in the 
field of glaucoma .We have seen that  open angle glaucoma may be 
associated with several different genes, each of which may produce a 
different time of onset and clinical course. Additionally, similar 
phenotypes can be seen with different mutations of different 
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chromosomes even within the same family. Probably there might be 
much more clarity about the genes and the way they may be responsible 
for different types of glaucoma in the near future.  
  
  
PART - II 
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AIMS AND OBJECTIVES 
AIM: 
To screen myocilin gene for pathogenic/non-pathogenic mutations 
in patients with positive family history of glaucoma  
OBJECTIVE: 
To analyze the role of myocilin gene variants and  its association in 
Indian families attending our glaucoma clinic. 
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MATERIALS AND METHODS 
This is a prospective study consisting of patients who attended 
glaucoma services of Regional Institute of Ophthalmology in the period 
of June 2011to June 2013 (2 years). The study enrolled 12 families 
comprising of 35 subjects which included the proband as well as the 
siblings and parents. 
INCLUSION CRITERIA: 
Patients with positive family history of glaucoma 
EXCLUSION CRITERIA: 
Glaucoma patients without positive family history  
Secondary glaucomas 
Congenital glaucoma   
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MATERIALS REQUIRED FOR GENE ANALYSIS 
Chemicals: 
Chemical used in the molecular study were purchased from 
standard chemical companies unless otherwise mentioned. 
EDTA, Ethanol, sodium chloride, sodium hydroxide pellets, Tris 
base, 100bp ladder DNA.    
Agarose, Ethidium Bromide, primers 
PCR purification kit 
Amplifier Profile for Myocilin: 
The details of oligonucleotide primers used for the amplification of 
myocilin (Exon1, Exon2, Exon3) 
Primer Sequence (5’- 3’) 
Tm 
(C) 
Ta 
(C) 
Amplicon 
Size(bp) 
Exon 1 
Forward 
Exon 1 
Reverse 
ACAGCAGAGCTTTCCAGAGG 
 
CATCTCACCCGGTCCTTTTA 
63.7 
 
63.7 
 
63.7 
 
   927 
Exon 2 
Forward  
Exon 2  
Reverse  
GCCCAACTGTTATCAGCACAGTC 
 
TCCCCTCCCTCTGCTCCCAG 
 
66.8 
 
72.2 
 
69 
 
  770 
 
 
 
 
1103 
Exon 3  
Forward  
 
Exon 3 
Reverse   
 
CTGAAAGTCACACAGCCAGCG 
 
GGTGACCATGTTCATCCTTCTGG 
 
 
68.3 
 
68.7 
 
 
 
68.7 
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Reagents: 
RBC Lysis Buffer  
Ammonium chloride - 155mM (8.29g) 
EDTA                       -0.1mM (1.00g) 
NaHCO3                  -12mM (0.034g) 
Adjust pH to 7.4 with 1M HCl or NaOH; make up to 1000ml with 
distilled water. Autoclave and store at room temperature. 
WBC Lysis Buffer 
 NA2EDTA              -25mM (8.14g) 
 NaCl                       -200mM (11.69g) 
Adjust pH to 8.0 with 1M NaOH, make up to 1000ml with distilled 
water, autoclave and store at room temperature 
Proteinase K (10 mg/ml) 
Proteinase K              - 100mg 
TE(Tris EDTA)          -10ml 
Dissolve 100mg proteinase K in 10ml TE for 30min at room 
temperature and store it at -20϶C. Proteinase K is the enzyme commonly 
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employed for digestion of proteins. It is a highly active protease from the 
mold Tritirachium album. 
Sodium dodecyl sulphate (SDS) 10%SDS – 10 gram.(Add water to 
make up to 100 ml, stir on a magnetic stirrer, filter and store at room 
temperature.) 
Phenol (Saturated,pH 8) 
Phenol: Chloroform: Isoamyl alcohol mixture 
  To prepare Phenol: Chloroform: Isoamyl alcohol mixture mix 25 
parts of phenol, 24 parts of Chloroform and 1 part of isoamyl alcohol. 
Isopropyl Alcohol 
  The action of isopropyl alcohol is to precipitate the DNA leaving 
RNA and polysaccharides in the solution. 
70% Ethanol 
Ethanol – 70 ml 
Distilled water – 30 ml 
It removes residual salt and moisture in the precipitated DNA. 
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Tris-EDTA (1 X TE) Buffer (pH – 8.0) 
Tris base – 1.2114 gram  
EDTA – 0.0372 gram 
Dissolve in 900 ml distilled water and adjust the pH to 8.Make up 
the volume to 1000 ml. Filter autoclave and store at 4϶C. 
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METHODOLOGY 
CLINICAL EVALUATION: 
All subjects who were enrolled in the study underwent a detailed 
historical evaluation which included age of onset of the disease, number 
of family members affected, detailed medical and surgical history, history 
of consanguineous marriage and pedigree details.  
They were then subjected to a comprehensive ophthalmic 
examination including refraction, estimation of best corrected visual 
acuity, and measurement of intraocular pressure (IOP) by Goldmann 
applanation tonometry, measurement of central corneal thickness (CCT) 
by ultrasonic pachymetry.The CCT corrected IOP was taken for analysis.  
Testing of visual acuity, slit lamp examination of the anterior 
segment, examination of the fundus by 90D, gonioscopy using four 
mirror  ,  fields  by  octopus  perimetry,  RNFL  and  optic  nerve  head  
topographic analysis by SD-OCT was done. 
The blood samples were collected from the probands and the 
siblings and parents whoever were available after written informed 
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consent.This study was approved by Institutional Human Ethical 
committee, Madras Medical College, Chennai  
PROCEDURE FOR GENOMIC DNA ISOLATION: 
Using Phenol-Chloroform-iso amyl alcohol method 
x 5 ml of the patient’s blood sample as well as their family members 
who were available was collected using EDTA containing 
vacutainer. 
x The collected blood sample was first centrifuged at 3500 rpm for 
30 minutes. 
x After centrifugation the sample gets separated into 3 different 
phases, first layer containing plasma, middle layer containing 
WBC and the last layer containing RBC. The WBC layer appears 
like a Buffy coat. 
x The WBC layer is taken carefully and transferred to a fresh tube. 
x To the separated layer add double the amount of RBC lysis buffer 
and vortex it. Repeat the steps until the pellet is devoid of red 
colour.  
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x Add working WBC lysis buffer (500-1000µl), with 1% SDS and 
Proteinase K, after adding the buffer do not disturb the tubes and 
keep it for overnight incubation in the water bath (37ÛC). 
x After overnight incubation in water bath at 37ȗC , add equal volume 
of Phenol-Chloroform-Isoamyl alcohol(24:24:1) and shake it well 
till the whole solution becomes milky white. 
x Centrifuge the sample at 11000rpm for 20minutes at 25ȗC. 
x The sample gets separated into three phases-aqueous, organic and 
white. 
x Take the aqueous phase and dissolve it in ice cold absolute alcohol 
(2.5ml).Shake it well. 
x The DNA will be visible like a thread and will assume the shape of 
a cotton ball. 
x Add 1 ml of 70% ethanol to the labeled eppendorff tubes. Suspend 
the DNA into it and spin it at 4ȗC with a speed of 11000rpm for 
about 20 minutes. 
x The Ethanol was discarded and the pellet is air-dried in a sterile 
place for 3 hours to remove any trace of residual ethanol. 
x Approximate amount of 1 X TE buffer was added according to the 
size of the pellet, allowed to dissolve and stored at -20϶C 
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Preparation of primers: 
 The  stock  solution  of  primers  was  having  concentration  of  100  
pm/µl.  working  solution  of  10  pmol/µl  was  prepared  by  adding  2µl  of  
stock solution of primers 18µl of sterile milliQ water. 
Concentration and purity were checked using Nano drop (Thermo 
scientific, Germany) 
Concentration of DNA: 
Concentration of double stranded DNA sample (µg/µl) = A260 × 50 
Purity of DNA: 
Pure DNA= A260/A280  1.8 
<1.8 indicates protein and phenol contamination  
>2.0 indicates the possible contamination of RNA 
Polymerase Chain Reaction (PCR): 
Principle: 
The PCR is a process in which minuscule amounts of DNA can be 
amplified to enormous amounts in a matter of hours. The original DNA 
strand is used as a template to synthesize a new strand, each of which 
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then serves as a template for a new strand, and so forth geometrically. 
The process is highly automated and results in sufficient DNA to give a 
reliable test when gene probes are used. 
PCR Conditions for MYOC 
PCR Conditions- MYOC Ex-1 
Steps Temperature 
(0C) 
Time Cycles (N) 
Initial 
denaturation 
950C 5 min 1 
Denaturation 940C 45sec 29 
Annealing 63.7ºC 45sec 29 
Extension 720C 45sec 29 
Final extension 720C 7 min 1 
 
PCR Conditions – MYOC Ex-2 
Steps Temperature 
(0C) 
Time Cycles (N) 
Initial 
denaturation 
950C 5 min 1 
Denaturation 950C 45sec 29 
Annealing 69ºC 45sec 29 
Extension 720C 45sec 29 
Final extension 720C 7 min 1 
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PCR Conditions- MYOC Ex-3 
Steps Temperature 
(0C) 
Time Cycles (N) 
Initial 
denaturation 
950C 5 min 1 
Denaturation 950C 45sec 29 
Annealing 68.7ºC 45sec 29 
Extension 720C 45sec 29 
Final extension 720C 7 min 1 
 
PCR Product Purification: 
The PCR product is purified by using “Qiagen PCR purification kit” 
x Add 5 volume of buffer PB to 1 volume of the PCR reaction and 
mix. If the colour at the mixture is orange or violet add 10 µl 3M 
sodium acetate, pH 5 and mix. The colour of the mixture turns 
yellow. 
x Place QIA quick column in a provided 2ml collection tube.  
x To bind DNA apply the sample to the QIA quick column and the 
centrifuge for 30-60 seconds at 8000 rpm. Discard flow through 
and place the QIA column back into the same tube. 
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x To wash add 0.75 ml buffer PE to the QIA quick column. 
Centrifuge for 30-60 seconds at 8000 rpm. Discard flow through 
and place the QIA column back into the same tube. 
x Centrifuge the QIA quick column once more in the provided 2 ml 
collection tube for 1 minute to remove residual wash buffer. 
x Place each QIA quick column in a clean 1.5 ml micro centrifuge 
tube. 
x To  elute  DNA,  add  50µl  EB  buffer  (10mM  Tris  cl,  pH  8.5)  or  
water(pH  7-8.5)  to  the  centre  of  the  QIA  quick  membrane  and  
centrifuge the column for 1 minute for increased DNA 
concentration,  add  20µl  of  the  elution  to  the  centre  of  the  QIA  
quick membrane, let the column stand for 1 minute and then 
centrifuge at 5000 rpm for one minute. 
x If  the  purified  DNA  is  to  be  analyzed  on  a  gel  add  1volume  of  
loading  dye  to  5  volume  of  purified  DNA.  Mix  the  solution  by  
pipetting up and down before loading the gel. 
Agarose Gel Electrophoresis; 
The amplicons were visualized in a 2% agarose gel in TBE buffer 
stained with Ethidium Bromide. The 2% gel was prepared by melting 
0.60 g of agarose powder in 30 ml of TBE (0.5X, pH 8.0) buffer in 
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microwave oven. The molten agarose was then cooled to 6000c;  2µl  of  
EtBr  was  added  to  it  and  poured  in  to  a  gel  casting  unit  after  both  the  
edges were sealed with cellophane tapes. When the gel is set, about 4µl of 
PCR sample and 1µl of gel loading dye (3X) were loaded and 
electrophoresed at a constant voltage of 75 volt and 125 mA for 
approximately 30 to 45 minutes or  till  the dye reaches two thirds of  the 
gel. After the electrophoresis the gel was visualized in UV-
transilluminator 
Sequencing of the purified PCR products: 
Purified PCR product is commercially sequenced with the forward 
primer at Amnion Biosciences Pvt.Ltd, Bangalore. 
BLASTN analysis: 
The sequences were aligned for homology with their respective 
reference sequences using NCBI BLASTN and analyzed for probable 
sequence variations depictive of either polymorphism or putative 
mutation. 
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OBSERVATION AND RESULTS  
4906 patients who attended our glaucoma clinic during the period 
June 2011 to June 2013 were evaluated for the presence of glaucoma and 
any family history of glaucoma if present was noted. Among these 
patients, 59 patients were having a history of glaucoma in their families 
and among them, 32 patients were found to be having established 
glaucoma, 21 were found to be glaucoma suspects and 6 of them had no 
evidence of glaucoma. Among 32 patients, around 12 of them were 
diagnosed to have primary open angle glaucoma which constitutes around 
37.5% of the patients with POAG having positive family history of 
glaucoma. 
12 families were included in this study comprising of 35 subjects  
In each family all available family members were evaluated clinically and 
their  blood  samples  subjected  to  DNA  analysis  after  getting  consent  of  
the patients. 
AGE DISTRIBUTION  
Onset of primary open angle glaucoma is usually in the 4th-6th 
decade in most of the patients except for a few who present early who are 
termed as having juvenile onset open angle glaucoma. 
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In our study among the 12 families, each family consisted of a 
proband whose siblings and parents whoever available was included. 
Among the 12 probands majority were in the age group of 50-70 years. 
 
Figure 1 – Age distribution among the probands 
SEX DISTRIBUTION  
                There is no gender predilection for development of primary 
open angle glaucoma and among 12 probands included in our study 8 of 
them were females and 4 were males. 
 
Figure 2- Sex distribution among the probands 
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IOP DISTRIBUTION  
Intraocular pressure was measured using Goldmann applanation 
tonometry and the IOP measured was corrected for central corneal 
thickness. The mean IOP in normal population is 15.8 +/- 2.8 mmhg. 
Majority of patients had their intraocular pressure within the normal 
range.  Only  5  persons  had  IOP  above  the  normal  range.  Few  of  them  
were already on treatment with topical medications, few were just 
glaucoma suspects and few patients had already undergone antiglaucoma 
surgery.  
 
Figure 3 – IOP distribution 
 
  
0
5
10
15
20
25
30
10-21 21-40 >40
RE
LE
53 
 
CUP: DISC RATIO 
Normal cup: disc ratio for a normal size disc is around 0.3-0.5. 
They are larger in eyes with larger cups and smaller in eyes with small 
cups. Glaucoma is suspected in case of an asymmetry of CD ratio > 0.2 
between 2 eyes, presence of other characteristic vessel changes along 
with presence of NRR thinning. Slit lamp biomicroscopy with 90D was 
done to assess the disc size and all patients in our study had disc size 
within the normal range of 1.5+/-0.5mm. Around 16 patients had 
moderate glaucomatous damage with cup: disc ratio of 0.5-0.7 whereas 8 
patients had advanced cupping with CD ratio of 0.8-0.9.  
 
 
 
 
Figure 4 – Distribution of Cup: Disc Ratio 
 
GONIOSCOPY 
Gonioscopy was done in all the patients using posner 4 mirror 
gonioscope and grading of angles was done based on the modified 
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Shaffer’s grading. Grade1 or less in more than 2 quadrants were 
categorised as having narrow angles. Our study was comprised of 
predominantly patients with open angles except for 2 of them who had 
closed angles.     
 
 
 
 
 
Figure 5 Gonioscopy 
VISUAL FIELDS  
Visual fields were assessed using OCTOPUS perimeter (301). A 
minimum of 3 fields were recorded, if any field defect was noted to 
determine if the field defect is persistent or not. The field defects were 
considered to be reliable if false positives and false negatives were less 
than 33% and fixation losses were below 20%. Majority of patients had 
their visual fields within normal limits. Tubular fields were noted in 2 
patients who had advanced glaucomatous damage. Visual fields could not 
be  assessed  in  2  patients.  One  of  them had  very  poor  vision  in  both  the  
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eyes while the other had poor vision only in 1 eye and hence field 
assessment could not be carried out. 
 
Figure 6 Visual fields by Octopus perimeter 
RNFL THICKNESS IN OCT  
Optical coherence tomography is a tool used to assess the retinal 
nerve fibre layer thickness (RNFL) and study the optic nerve head 
topography as well as macular topography. In glaucoma it is 
predominantly used to evaluate the RNFL thickness and to analyse 
whether the disease is progressing or not. Mainly helps in detecting pre 
perimetic stage of glaucoma as field defects arise only if a minimum of 
30% of RNFL is damaged. All patients underwent imaging by spectral 
domain optical coherence tomography in both eyes. (OTI ophthalmic 
technologies OCT / SLO COMBINATION IMAGING SYSTEM V 1.37 
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was used for all patients).Average RNFL thickness in normal population 
varies from 103.07±10.13µ (Archana Malik et al, 2010). In our study, 
RNFL thickness was found to be below 100 µ in 12 patients with 2 
patients having a thickness of lesser than 90µ.  
 
Figure 7. Distribution of RNFL thickness assessed using OCT 
 
MODE OF TREATMENT IF ANY  
Once primary open angle glaucoma is diagnosed medical treatment 
with topical antiglaucoma medications is the first line of treatment. If the 
disease progresses despite maximal tolerated medical therapy the patient 
is taken up for antiglaucoma surgery namely trabeculectomy which is the 
gold standard. In our study 17 patients were just observed and were on 
regular follow up and were not on any mode of treatment. 11 patients 
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were on topical antiglaucoma medications. 6 patients had undergone 
surgical treatment of which 2 patients had their IOP under surgical 
control while the remaining 4 were started on topical antiglaucoma 
medications due to poor surgical control of IOP. 
 
Figure 8 – Different modes of treatment the patients had underwent 
 
DNA QUANTIFICATION DATA (Using nanodrop) 
Sample ID Nucleic acid concentration (ng/µl) 
Absorbance ratio 
260/280 
DKEG1A         2468.0             1.81 
DKEG1B         2055.9             1.87 
DKEG1C         3480.0             1.80 
DKEG1D         2046.2             1.88 
DKEG2A         1655.8             1.84 
DKEG2B          408.2             1.83 
DKEG3A         1791.5             1.84 
DKEG3B         1216.6             1.86 
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DKEG3C         1181.7             1.87 
DKEG3D           360.5             1.81 
DKEG4A           258.2             1.82 
DKEG4B         1506.4             1.85 
DKEG4C         2932.6             1.82 
DKEG4D         1283.4               1.83 
DKEG5A           271.0             1.84 
DKEG5B           875.8             1.81 
DKEG6A          1858.3             1.84 
DKEG6B            733.8              1.82 
DKEG6C            718.2             1.86 
DKEG7A          3440.0             1.85 
DKEG7B          1069.5             1.81 
DKEG8A          4046.8             1.84 
DKEG8B          2322.0             1.82 
DKEG8C          3013.2             1.86 
DKEG9A          2377.7             1.81 
DKEG9B          2351.4             1.83 
DKEG10A          2269.3             1.83 
DKEG10B            121.5             1.78 
DKEG11A            371.5             1.88 
DKEG11B          1484.1             1.84 
DKEG12A          2120.4             1.84 
DKEG12B          2868.4             1.88 
DKEG12C          1844.0             1.86 
DKEG12D          2574.2             1.81 
DKEG12E          2270.1             1.84 
 ELECTROPHEROGRAM OF MYOCILIN EXON 1 
 
 
 
 
 
                        
 
 
 
 
ELECTROPHEROGRAM OF MYOCILLIN EXON 2 AND EXON 3 
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MUTATIONS/SNP’S IN MYOC IN SOUTH INDIAN PATIENTS 
ATTENDING OUR GLAUCOMA CLINIC  
FAMILY ID NUCLEOTIDE CHANGE EXON 
AMINO 
ACID 
CHANGE 
GENOTYPE INTRONIC VARIATIONS 
DKEG1A c.227G>A Exon 1 R76K Homozygous        NO 
DKEG1A c.605-374 C>G      -      - Homozygous      YES 
DKEG1A c.605-280 T>G      -       - Homozygous       YES  
DKEG3A c.605-374 C>G      -      - Homozygous      YES 
DKEG3A c.605-332 G>A      -      - Heterozygous       YES 
DKEG3A c.730+35 G>A      -      - Homozygous      YES 
DKEG4A c.605-374 C>G      -      - Homozygous       YES 
DKEG4A c.605-332 G>A      -      - Heterozygous       YES 
DKEG4A c.605-280 T>G      -      - Heterozygous      YES 
 
DKEG4A c.730+35 G>A      -      - Homozygous      YES 
DKEG5A c.605-374 C>G      -      - Homozygous       YES 
DKEG5A c.605-303 C>G      -      - Heterozygous      YES 
DKEG5A c.605-280 T>G      -      - Heterozygous       YES 
DKEG5A c.730+35 G>A      -      - Heterozygous       YES 
DKEG6A c.227G>A Exon 1  R76K Heterozygous NO 
DKEG6A c.605-374 C>G     -     - Homozygous     YES 
DKEG6A c.605-280 T>G     -     - Homozygous     YES 
DKEG6A c.730+35 G>A     -     - Homozygous     YES 
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DKEG7A c.227G>A Exon 1 R76K Heterozygous     NO 
DKEG7A c.604+136G>A     -     - Homozygous     YES 
DKEG7A c.605-374 C>G     -     - Homozygous     YES 
DKEG7A c.605-332 G>A     -     - Heterozygous     YES 
DKEG7A c.605-280 T>G     -     - Heterozygous     YES 
DKEG7A c.730+35 G>A     -     - Homozygous      YES 
DKEG9A c.605-374 C>G     -     - Homozygous     YES 
DKEG9A c.605-280 T>G     -     - Heterozygous     YES 
DKEG9A c.730+35 G>A     -     - Homozygous     YES 
DKEG9A c.1041 T>C Exon 3 Y347Y Heterozygous       NO 
DKEG10A c.605-374 C>G  -     - Heterozygous     YES 
DKEG10A c.605-332 G>A -     - Heterozygous     YES 
DKEG10A c.730+35 G>A  -     - Heterozygous     YES 
DKEG11A c.1102 C>T Exon 3 Q368X Heterozygous      NO 
DKEG12A c.227G>A Exon 1 R76K Homozygous      NO 
DKEG12A c.974 C>T Exon 3 T325M Heterozygous      NO 
DKEG12A c.1045 C>T Exon 3 L349L Heterozygous      NO 
DKEG12A c.1410 C>T Exon 3 R470R Heterozygous      NO  
 
 
 
 
PHENOTYPIC PICTURE OF DKEG11A 
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LEFT EYE SHOWING BLEB WITH PERIPHERAL IRIDECTOMY              
 
 
 
 
 
 
 
 
 
 
 
 
  
 
GONIOSCOPY  
RIGHT EYE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
I - Inferior  angle as seen in superior mirror  
S - Superior angle as seen in inferior mirror 
N - Nasal angle as seen in temporal mirror 
T - Temporal angle as seen in nasal mirror  
 
 
 
 
 
I 
T 
S 
N 
GONIOSCOPY  
LEFT EYE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I - Inferior  angle as seen in superior mirror  
S - Superior angle as seen in inferior mirror 
N - Nasal angle as seen in temporal mirror 
T - Temporal angle as seen in nasal mirror     
I 
N T
S 
 OPTIC NERVE HEAD 
 
RIGHT EYE      LEFT EYE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 OPTICAL  COHERENCE TOMOGRAPHY 
RETINAL NERVE FIBRE LAYER THICKNESS 
RIGHT EYE 
 
 
 
 
 
 
 
 
 
 
 
LEFT EYE 
 
 
 
 
 
 
 
 
 
 OPTIC NERVE HEAD TOPOGRAPHY 
 
            RIGHT EYE                                                  LEFT EYE 
 



























DKEG1A Exon 1 BLASTN result 
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DISCUSSION 
Glaucoma is the second leading cause of blindness worldwide and 
is characterized by progressive optic nerve head damage for which 
intraocular pressure is one of the most important risk factor. It usually 
begins in middle aged individuals around 4th decade and progresses 
slowly but relentlessly. The disease process is insidious and most of the 
patients remain asymptomatic unless the damage is advanced leading to 
deterioration of vision. Hence most of the patients remain undiagnosed or 
untreated. Although the clinical course of the disease is well known the 
molecular events responsible for glaucoma are currently poorly 
understood and current therapeutic strategies are not curative. 
Globally this disease affects 60 million people, among them 8.4 
million people have bilateral blindness due to glaucoma. This is predicted 
to increase to 80 million and 11.2 million respectively by the year 202015. 
In India, approximately 11.2 million persons aged 40yrs and older are 
estimated to be suffering from glaucoma of which POAG is estimated to 
affect 6.48 million people.16 In general globally 1.12% among the whole 
population is suffering from glaucoma. This data is not a true projection 
as this does not include north Indian population. When that is taken into 
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account it might be hiked even more. In the present study out of 4906 
patients, 59 (1.2%) of them have a family history of glaucoma.  
Primary open angle glaucoma (POAG) is the most common type of 
glaucoma, affecting almost 2% of the world’s population. The prevalence 
of POAG in south Indian population is about 1.6% which is similar to 
that observed in Western population 17.   In  this  study  among  the  59  
patients with positive family history, 32 were affected with glaucoma, out 
of which 37.5% (N=12) of them have primary open angle glaucoma.  
Over the past one decade of work in molecular genetics of 
glaucoma 29 genetic loci have been identified for various forms of 
glaucoma through linkage analysis18, 19. Over 12 candidate loci were 
reported, of which myocilin is the first gene identified to be associated 
with glaucoma. It is formerly called as TIGR (Trabecular meshwork–
Induced Glucocorticoid Response protein).20 It was presumed that 
myocilin is one of the aqueous outflow regulators in cells. Earlier it was 
known to express in the ciliary body and trabecular meshwork however 
its presence in the trabecular cells of the uveal, corneoscleral, and 
juxtacanalicular regions and the endothelial cells of Schlemm’s canal  
were documented through functional studies.21,22,23Hence this explains as 
to how it regulates the aqueous flow in and out of the cells. Till now the 
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only gene that causes elevated IOP with normal development of the 
ocular anterior segment is myocilin24.  Gene-specific pathophysiology is 
not well characterized for candidate genes of glaucoma. Hence this calls 
for more molecular studies in glaucoma to validate its role in the 
pathophysiology of the disease.  
Globally myocilin mutations in primary open angle glaucoma are 
approximately about  2-5%25,26,27.  Whereas  in  Indian  population,  a  
frequency of roughly 7.1%  and 2% has been documented28,12,29. 
In the present study, 12 families comprising of 35 patients were 
investigated. Most of the affected individuals were in the age group of 
50-70yrs. Two of the patients had juvenile onset of the disease and 
majority of them were females. In the present study two missense 
variations viz., R76K (c.227G>A), that was found to be homozygous in 
two of the probands (DKEG1A and DKEG12A), while heterozygous in 
two other probands (DKEG6A; DKEG7A) and T325M (c.974 C>T) in 
the proband DKEG12A and a nonsense mutation as Q368X c.1102 C>T 
in the proband DKEG11A were observed. A couple of variations in the 
intronic region of myocilin gene, which includes c.604+136G>A as a 
homozygous allele in the proband DKEG7A were also documented. The 
intronic variation c.605-374 C>G  was found in most of the probands in a 
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homozygous state  (DKEC1A; DKEG3A; DKEG4A; DKEG5A; 
DKEG6A;  DKEG7A; DKEG9A) and in one control subject (DKC150), 
whereas this was found to be heterozygous in another proband 
(DKEG10A). The intronic variation c.605-332 G>A occurs in 
heterozygous condition in some of the probands (DKEG3A; DKEG4A; 
DKEG7A; DKEG10A), whereas the intronic variation c.605-303 C>G is 
found only in one proband DKEG5A. The intronic variation c.605-280 
T>G  in a heterozygous state is found in  most of the probands 
(DKEG4A; DKEG5A; DKEG7A; DKEG9A) and in one control subject 
(DKC150),and the same  variation was found to be homozygous in two of 
the proband studied. The intronic variation c.730+35 G>A was found to 
be in homozygous form in most of the probands (DKEC1A; DKEG3A; 
DKEG4A; DKEG6A; DKEG7A; DKEG9A) and in one control subject 
(DKC150) studied. 
Three synonymous variations have been documented such as 
Y347Y (c.1041 T>C) in the proband DKEG9A and two other as L349L 
c.1045 C>T R470R c.1410 C>T in a single proband (DKEG12A). 
The documented mutation Q368X poses a 4.7-fold increased risk 
of POAG in the global population30.  For the first time this mutation was 
identified in a patient of south Indian origin and who had advanced 
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glaucoma. Express shunt was performed in the right eye whereas in the 
left eye trabeculectomy, the gold standard procedure was done. The IOP 
was not under surgical control and patient was put on topical 
antiglaucoma medications. The CD ratio in both the eyes was 0.9 and 
visual fields showed presence of advanced field defects with only tubular 
field remaining. 
The proband DKEG 12 A is  of  interest  as   she was found to be a 
compound heterozygote carrying two variations (R76K; T325M), 
amongst  which one is a novel mutation (T325M) and two  were of  
synonymous snps (L349L; R470R).She was also an established case of 
primary open angle glaucoma.  Her fundus showed 0.9 cupping in both 
the eyes and she was on topical antiglaucoma medications. 
More than 50 mutations have been reported in myocilin gene 
causing POAG, Q368X mutation occurs most frequently in patients with 
POAG. Functional study of this mutation, gives us an insight into the 
pathology caused by this variation31.  It  is  a  well  known fact  that  as  age  
advances the outflow resistance increases, accompanied by reduction in 
the trabecular meshwork cells and alterations in the juxtacanalicular 
extracellular matrix32, 33. This fact was supported by the work of Alvarado 
et al. (1986)34, wherein they have reported that glaucomatous eyes exhibit 
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fewer TM cells and an abnormal appearance of ECM in the 
juxtacanalicular region. 
Sohn et al (2002) has also reported an aggregated expression of the 
mutant myocilin, thereby causing proteolytic degradation31. The 
accumulation of the degraded protein causes cytotoxic effect and 
contributes to degenerative disease marked by the formation of insoluble 
protein plaques, which is characteristic of neurodegenerative diseases. 
Myocilin  normally  exists  either  as  a  dimer  or  as  an  oligomer,  
wherein oligomerisation between wild type and truncated myocilins, 
leads to colocalisation of truncated myocilin (Q368X) with wild type 
myocilin31. They have also shown that secretion of wild-type myocilin is 
suppressed when co expressed with truncated myocilin. Localization of 
wild type myocilin to microtubules of mitochondria, or to cross-linked 
actin networks was not observed, which is in contradictory to the 
previous work35, 36, 37, 38.  
The other variation (T325M) has to be characterized functionally to 
deduce its effect on the pathology of POAG. This variation was reported 
in NCBI SNP database, as observed in an individual documented from a 
population based cohort study of exome variation in cardiovascular 
disease, of north American origin. But for the first time we have 
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identified this in a patient with POAG. There is a lacunae of population 
data about this variation. Hence this has to be characterized both by 
population study and functional analysis before finding association with 
POAG. 
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SUMMARY  
This prospective study was carried out enrolling 12 families 
comprising of 35 subjects over a period of two years from June 2011 to 
June 2013. 35 subjects comprised of the proband and their siblings or 
parents if available. All patients underwent a thorough ophthalmological 
examination after obtaining a detailed history covering the pedigree 
details. Ethical clearance for this study was obtained from Institutional  
Human Ethical Committee,  Madras medical College, Chennai. On 
securing informed consent, the blood samples were collected and 
subjected to DNA analysis. We collected a minimum of two samples and 
a maximum of five  samples per family  depending on the availability. 
In our study majority of the probands were females in the age 
group of 50-70 years. The intraocular pressures recorded were normal in 
majority of the patients while five of them had their intraocular pressures 
above the normal range.  
Few (DKEG1A, DKEG2A, DKEG2B, DKEG6A, DKEG6C, 
DKEG7A, DKEG7B, DKEG8A, DKEG9A, DKEG10A, DKEG10B, 
DKEG12A) were already on treatment with topical antiglaucoma 
medication, while some (DKEG1B, DKEG3A, DKEG4A, DKEG5A, 
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DKEG5B, DKEG11A) had undergone antiglaucoma surgery and others 
were just glaucoma suspects. Around 16 patients had moderate 
glaucomatous damage and eight of them had advanced glaucoma. 
Gonioscopy  when performed showed closed angles in two patients, rest 
had open angles. Retinal fibre layer thickness (RNFL) was found to be 
below 100  µ  in  12  patients   and  in   two of  the   patients   thickness  was  
found to be lesser than 90µ. 
Amongst  the 35 subjects, 17 were just glaucoma suspects and 
hence were kept under observation. Eleven patients were put on topical 
antiglaucoma medications and six patients had undergone antiglaucoma 
surgery out of which two of them had their IOP under surgical control 
while remaining four were  on topical antiglaucoma medications post 
operatively. 
DNA analysis was done which showed exonic variations in six of 
the probands of which three had variations in exon 1, two in exon 3 and 
one had in both exon 1 and exon 3. All these exonic variations were 
found to be  of heterozygous nature  except two  that were homozygous. 
The proband DKEG12A had four exonic variations one in exon 1 
viz., R76K which was homozygous and other three were in exon 3 as 
T325M, L349L, R470R all were heterozygous. The change T325M is a 
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novel variation, that has been reported in a cohort study of exome 
sequencing (NCBI database). Its precise role in causing glaucoma is as 
yet undetermined, as there is no report of this variation in POAG. Two of 
the novel synonymous variations viz., L349L, R470R are being 
documented for the first time to be in association with glaucoma.  
The proband DKEG11A  had  Q368X in heterozygous state which 
is a truncated mutation. This mutation has earlier been reported in 
western populations as well as in another study involving the north Indian 
population.  
There were many intronic variations noted in probands DKEG3A, 
DKEG4A, DKEG5A, DKEG7A, DKEG9A, DKEG10A, and DKEG12A. 
Some were heterozygous and others were homozygous variations. 
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CONCLUSION  
In this study, patients having positive family history of glaucoma 
were evaluated to assess the role of genetic screening in early detection of 
this dreaded disease.  
For the first time a truncated mutation viz., Q368X was detected in 
one of the patients (DKEG11A) which has previously been reported in a 
western population. Similar mutation has also been reported in a study 
from north India. But this is the first time this mutation is being reported 
in a south Indian population. Studies have indicated  a 4.7 fold increased 
risk of POAG in patients carrying this mutation.30 This patient had an 
advanced glaucomatous damage in both eyes and had undergone shunt 
surgery (EXPRESS SHUNT) in his right eye while trabeculectomy in his 
left eye. However his intraocular pressures were not under surgical 
control and had to be started on topical antiglaucoma medications post 
operatively. This probably suggests that this variation might also be 
responsible for the severity of the disease presentation. 
The variation (T325M) was identified in a proband DKEG12A 
who was clinically documented to have open angles. This patient also had 
a tubular field of vision with advanced glaucomatous changes in the optic 
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disc and was on topical antiglaucoma medications. A perusal of the 
literature pointed out documentation of this in a population based cohort 
study of exome variation in a north American population (NCBI-dbSNP 
database). It has to be characterized functionally to deduce its effect on 
the pathology of primary open angle glaucoma.  
In conclusion molecular screening of myocilin gene in glaucoma 
patients might aid in early diagnosis and treatment there by imparting a 
better visual prognosis to the patients for efficient clinical management 
and lessening the burden of morbidity.  
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ABBREVIATION 
CCT            -    Central corneal thickness 
ECM            -    Extracellular matrix  
HUGO        -    Human genome organisation 
IOP            -    Intraocular pressure  
JOAG        -  Juvenile onset open angle glaucoma 
MMP        -  Matrix metalloproteinase 
MYOC         -    Myocillin 
OCT            -    Optical coherence tomography 
OPTN          -    Optineurin 
PACG          -    Primary angle closure glaucoma 
PCG             -    Primary congenital glaucoma 
PCR          -  Polymerase chain reaction 
POAG          -    Primary open angle glaucoma 
RGC            -  Retinal ganglion cells  
RNFL         -    Retinal nerve fibre layer 
SITA           -    Swedish interactive threshold algorithm  
SNP’S          -         Small nuclear polymorphisms 
TIGR         -    Trabecular meshwork induced glucocorticoid response  
           protein 
TOP            -    Tendency oriented perimetry 
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GENETICS 
A   -   Adenine 
G   -   Guanine 
C   -   Cytosine 
T   -  Thymidine  
CODON FOR AMINO ACIDS 
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PROFORMA 
 
 
Case No        :                                                                                                              
Date              :                                                                               Unit      :    
O.P. No         :                                                                              GC NO  : 
 
 
Name of the Proband  
  
Date of Birth 
           
Age & Sex 
                
Fathers Name & 
Age:____________________________________________________ 
Affected:   Yes             No              
 
Mothers Name & 
Age:___________________________________________________ 
Affected:   Yes             No              
 
Siblings if any : ___________________________________________________ 
Affected:   Yes             No              
 
Address : 
_______________________________________________________________ 
                
________________________________________________________________ 
                
________________________________________________________________ 
Contact No: 
_____________________________________________________________   
 
 
Pedigree details:    
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 SLIT LAMP EXAMINATION  
 
 
Right Eye  Left Eye 
           Lids  
          Conjunctiva  
          Cornea  
          Anterior Chamber  
          Iris  
          Pupil  
          Lens    
 
     VISION  
        IOP  
        CCT  
     FUNDUS 
  CD RATIO 
NASALISATION 
BAYONETTING 
NRR THINNING 
 
  
 
   GONIOSCOPY 
(SHAFFER’S 
GRADING ) 
 
    
  AUTOMATED 
   PERIMETRY 
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                        RE         OCT                        LE 
     MACULAR 
 TOPOGRAPHY  
 
 
                                                              
          RNFL 
         ONH 
   DISC AREA 
 
   CUP  AREA 
 
   RIM  AREA 
 
   CD H RATIO 
 
   CD V RATIO 
 
CD AREA 
RATIO 
 
 
 
             
 
 
 
   
 
 
 
 
 
 
 
 
 
 
RE LE RE LE RE LE RE LE RE LE RE LE RE LE
1 DKEG1A Padmalatha 39 F YES 6/9 6/6 16 18 552 561 Open Open 0.8 0.7 SA SA 109 118
2 DKEG1B Meenakshi 69 F YES 6/6 6/6 14 14 540 545 Open Open 0.6 0.7 WNL SA IA 113 106
3 DKEG1C Srinivasan 35 M NO 6/6 6/12 12 14 535 544 Open Open 0.4 0.4 WNL WNL 115 101
4 DKEG1D Ganesh 36 M NO 6/6 6/6 14 16 565 560 Open Open 0.4 0.4-0.5 WNL WNL 105 110
5 DKEG2A Shanthi 62 F YES 6/9 6/9 12 12 570 572 Open Open 0.6 0.6 IA IA 88 93
6 DKEG2B Subbulakshmi 51 F YES 6/9 6/9 20 22 576 578 Open Open 0.6 0.6-0.7 IA NS 96 98
7 DKEG3A Vasantha Gokila 66 F YES PL 6/12 14 14 520 540 Open Open 0.9 0.6 NP IA NP 98
8 DKEG3B Karthikeyan 47 M NO 6/6 6/6 18 16 528 524 Closed Closed 0.5 0.4 WNL WNL 122 112
9 DKEG3C Bhuvaneshwari.P 45 F NO 6/6 6/6 18 18 529 520 Open Open 0.4 0.4 WNL WNL 115 118
10 DKEG3D Rajeshwari 43 F NO 6/6 6/6 16 16 520 520 Open Open 0.4 0.5 WNL WNL 120 101
11 DKEG4A Ramakrishnan 63 M YES NO PL 1/2 / 60 42 34 521 534 Open Open 0.9 0.9 NP NP NP NP
12 DKEG4B Muthu Chella Bharathi 24 M NO 6/6 6/6 12 18 570 576 Open Open 0.3 0.3 WNL WNL 105 113
13 DKEG4C Muthukala 24 F NO 6/6 6/6 12 12 525 579 Open Open 0.3 0.3 WNL WNL 116 118
14 DKEG4D Malathi 31 F NO 6/6 6/6 12 12 533 530 Open Open 0.3 0.3 WNL WNL 103 111
15 DKEG5A Ulagammal 43 F YES 6/6 6/6 18 18 545 540 Open Open 0.6 0.8 SA SA,IA 98 88
16 DKEG5B Somasundaram 40 M YES 6/6 6/6 18 16 534 530 Open Open 0.7 0.8 SA,IA SA,IA 96 90
17 DKEG6A Vignesh 18 M YES 6/6 6/6 24 24 593 623 Open Open 0.7 0.6 NS IA 96 98
18 DKEG6B Subashree 9 F NO 6/6 6/6 14 16 520 540 Open Open 0.5 0.4 WNL WNL 100 103
Fields
MASTER CHART
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OCT- RNFLSample 
Number
S.NO Sex
Affected
or not 
AgeName
BCVA IOP mmhg CCT ȝ Gonioscopy Fundus(CD Ratio)
RE LE RE LE RE LE RE LE RE LE RE LE RE LE
Fields OCT- RNFLSample 
Number
S.NO Sex
Affected
or not 
AgeName
BCVA IOP mmhg CCT ȝ Gonioscopy Fundus(CD Ratio)
19 DKEG6C Rajendran 47 M YES 6/12 6/12 12 12 540 520 Open Open 0.7 0.7 SA SA 94 98
20 DKEG7A Selvaraj 60 M YES 6/6 6/6 36 22 520 580 Open Open 0.7 0.8 IA IA 81 96
21 DKEG7B Surendar 24 M YES 6/6 6/6 20 34 574 578 Open Open 0.6 0.6-0.8      IA       SA,IA 98 88
22 DKEG8A Malini 53 F YES 6/6 6/6 22 18 531 522 Open Open 0.5 0.5 IA IA 100 98
23 DKEG8B Rekha 33 F NO 6/12 6/9 18 18 548 540 Open Open 0.4 0.4 WNL WNL 112 106
24 DKEG8C Krishnakumar 27 M NO 6/12 6/6 12 12 540 540 Open Open 0.5 0.3 WNL WNL 106 104
25 DKEG9A Bhuvaneshwari.A 53 F YES 6/6 6/6 16 14 520 525 Open Open 0.4 0.7 IA SA,IA 100 96
26 DKEG9B Banumathy 58 F NO 6/9 6/12 12 12 560 560 Open Open 0.3 0.3 WNL WNL 116 110
27 DKEG10A Suganthi 50 F YES 6/6 6/6 12 14 540 535 Open Open 0.8 0.8 SA,IA SA,IA 98 94
28 DKEG10B Rajkumar 21 M YES 6/6 6/6 18 20 520 540 Open Open 0.8 0.7 WNL WNL 104 110
29 DKEG11A Premanathan 57 M YES 6/6 6/12 32 38 560 574 Open Open 0.9 0.9 Tubular Tubular 95 97
30 DKEG11B Dinesh Kumar 22 M NO 6/6 6/6 12 12 540 540 Open Open 0.3 0.3 WNL WNL 104 106
31 DKEG12A Leelavathy 48 F YES 6/6 6/6 18 12 520 540 Open Open 0.9 0.9 Tubular Tubular NP NP
32 DKEG12B Rajathi 32 F NO 6/6 6/6 14 14 530 545 Open Open 0.6 0.5 WNL WNL 104 100
33 DKEG12C Shanthi 50 F NO 6/6 6/6 14 14 535 520 Open Open 0.4 0.4 WNL WNL 113 114
34 DKEG12D Varalakshmi 48 F NO 6/6 6/6 14 14 540 545 Open Open 0.5 0.5 WNL WNL 120 115
35 DKEG12E Krishnakumari 42 F NO 6/6 6/6 14 12 520 530 Closed Closed 0.6 0.6 WNL WNL 106 108
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KEY TO MASTER CHART 
 
BCVA                  -  Best corrected visual acuity 
IOP                       -  Intraocular pressure 
CCT                      -  Central corneal thickness 
CD Ratio               -  Cup: Disc ratio 
SA                         -  superior arcuate defect 
IA                          -  Inferior arcuate defect  
NS                         -  Nasal step defect 
WNL                     -  Within normal limits 
OCT                      -  Optical coherence tomography 
RNFL                    -  Retinal nerve fibre layer thickness 
NP                          -  Not possible  
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